March 16, 2017 / 6:10 AM / 8 months ago

BRIEF-Bone Therapeutics: cash at end of 2016 20.3 million euros

March 16 (Reuters) - Bone Therapeutics:

* Cash at end of 2016: 20.3 million euros ($21.78 million)

* Management team strengthened with appointments of Thomas Lienard (CEO)

* Operating income of 4.0 million euros for the full year 2016, compared to 3.8 million euros in full year 2015

* Operating loss for the period amounted to 12.8 million euros, compared to 12.2 million euros in full year 2015

* For 2017, we are expecting potential value inflection points in the second half of this year from our delayed-union fractures and spinal fusion clinical programmes Source text for Eikon: Further company coverage: ($1 = 0.9321 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below